More articles about Business, Policy & Funding

The firm cited "strong demand for pathology products and companion diagnostics services" for revenue gains in its Diagnostics and Genomics Group.

The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.

The immunoassay allows for the rapid detection of influenza types A and B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients.

The company issued more than 1.8 million shares of its common stock to several of its trade creditors to erase debt that it owed them, Precipio said in an SEC document.

The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.

Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.

Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.

The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.

MHRA has also published a draft guidance for institutions that offer such tests so that they can gain compliance with the new directive.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

The $649 NGS test screens for 193 disorders, can be ordered online, and is designed to supplement standard state newborn screening services. 

During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.

The company also estimated full-year 2017 revenues to be between $23.7 million and $24.0 million, and announced a $15.8 million contract in Ethiopia.

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.

Japan's Ministry of Health, Labor and Welfare has approved QuantiFeron-TB Gold Plus (QFT-Plus) as an in vitro diagnostic to detect tuberculosis infection.

DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.

The Sentosa SA201 HSV-1/2 PCR test detects herpes virus DNA from oral or anal skin lesions in symptomatic patients.

Pages